Idera Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
EXTON, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera or the Company) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020.
- EXTON, Pa., March 01, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Idera or the Company) (Nasdaq: IDRA) today reported its financial and operational results for the fourth quarter and year ended December 31, 2020.
- Since September 30, 2020, the following corporate updates were announced:
The Company closed a second tranche under its April 7, 2020 securities purchase agreement for additional aggregate gross proceeds of $5.0 million. - The Company appointed Daniel Soland as Senior Vice President and Chief Operating Officer as of January 4, 2021.
- R. Clayton Fletcher, Senior Vice President of Business Development and Strategic Planning, retired from the Company as of December 31, 2020.